Vir Biotechnology Names Interim CFO as Jason O'Byrne Steps Down

O'Byrne's Departure and Succession Timeline

Jason O'Byrne informed Vir Biotechnology on July 20, 2026, that he will be stepping down as Executive Vice President and Chief Financial Officer, effective August 3, 2026. The filing states that O'Byrne's decision to leave the company is driven by his pursuit of another opportunity. The disclosure explicitly notes that the resignation was not the result of any disagreement with Vir Biotechnology regarding the company's operations, policies, or practices, a standard representation that investors often monitor as an indicator of the nature of executive departures.

Following O'Byrne's announcement, Vir Biotechnology has initiated a search for his permanent successor. In the interim, the company has moved swiftly to ensure continuity in the chief financial officer function by appointing an internal candidate to the interim principal financial officer role. The transition timeline provides a two-week notice period, allowing for an orderly handoff of responsibilities during the critical August 3 effective date.

Brent Sabatini Appointed as Interim Principal Financial Officer

On July 23, 2026, three days after O'Byrne's resignation announcement, the Board of Directors of Vir Biotechnology appointed Brent Sabatini, CPA, MBA, to serve as interim principal financial officer of the company, effective August 3, 2026. Sabatini, age 52, has been serving as Senior Vice President and Chief Accounting Officer of Vir Biotechnology since February 2023 and has held the role of principal accounting officer since October 2024. His appointment to the interim CFO position represents a promotion from within the finance and accounting leadership team.

The filing confirms that there are no arrangements or understandings between Sabatini and any other persons pursuant to which he was selected for the interim principal financial officer role. Additionally, there are no family relationships between Sabatini and any director or executive officer of Vir Biotechnology. The company also disclosed that Sabatini has no direct or indirect interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K. These representations are standard governance disclosures designed to affirm the independence and appropriateness of the appointment.

Sabatini's Professional Background and Qualifications

Brent Sabatini brings more than two decades of relevant experience in finance and accounting leadership to his interim principal financial officer role. Prior to joining Vir Biotechnology, Sabatini was employed at Capsida Biotherapeutics, Inc. from March 2021 to February 2023, where he most recently served as Head of Finance. His tenure at Capsida provided him with experience in the biotherapeutics sector, an industry context directly relevant to his responsibilities at Vir Biotechnology. Before Capsida, Sabatini spent approximately seventeen years at Amgen Inc., from April 2004 to March 2021, where he progressed through various positions of increasing responsibility, including leadership roles in Accounting, Tax, and Financial Planning and Analysis. His tenure at Amgen, one of the world's largest biotechnology companies, afforded him exposure to complex financial, tax, and operational planning matters at scale.

Sabatini holds relevant professional credentials and educational qualifications. He is a Certified Public Accountant (CPA) and earned a Bachelor of Science degree in Accountancy from California State University, Northridge. He also holds a Master of Business Administration (MBA) from the University of Michigan's Stephen M. Ross School of Business. His CPA designation, MBA credentials, and progressive leadership roles across accounting, finance, and planning functions position him with the technical and strategic knowledge typically expected in a chief financial officer capacity, even in an interim capacity.

Compensation and Interim Arrangements

The filing explicitly states that Sabatini will not receive any adjustment to his compensation or any additional compensation in connection with performing the function of interim principal financial officer of Vir Biotechnology. This compensation arrangement suggests that the company is treating the interim CFO role as an extension of his current Senior Vice President and Chief Accounting Officer responsibilities rather than as a distinct, separately compensated position. This approach may reflect the company's expectation that the interim period will be of limited duration while the search for a permanent CFO successor proceeds.

The absence of incremental compensation for the interim principal financial officer role is noteworthy for investors monitoring executive compensation practices and the company's cost management posture. Interim arrangements that do not trigger additional compensation costs may indicate management's intent to efficiently manage the transition and avoid prolonged interim periods.

Governance and Disclosure Confirmations

The company's announcement includes standard governance confirmations required under securities regulations. The filing confirms that no arrangements or understandings exist between Sabatini and any other persons with respect to his selection as interim principal financial officer, a representation designed to ensure the appointment was made on the merits and not pursuant to any undisclosed agreements or side arrangements. Similarly, the disclosure confirms the absence of family relationships between Sabatini and any director or executive officer of Vir Biotechnology, addressing potential conflicts of interest or nepotism concerns.

The filing also confirms that Sabatini has no direct or indirect interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K, which covers related-party transactions and conflicts of interest. These governance confirmations are standard practice in executive appointment announcements and are intended to provide assurance to investors regarding the independence and propriety of the selection process and the absence of material undisclosed conflicts.

Principal Accounting Officer Role and Financial Leadership Continuity

Prior to his interim principal financial officer appointment, Sabatini has held the title of principal accounting officer since October 2024, a role that carries specific responsibilities under the Sarbanes-Oxley Act and securities regulations. His established position as principal accounting officer, combined with his senior vice president title and Chief Accounting Officer responsibilities, provided him with significant visibility into Vir Biotechnology's accounting policies, internal controls, and financial reporting processes. This existing familiarity with the company's accounting functions may facilitate a smoother transition to the interim principal financial officer role than an external appointment might provide.

The filing indicates that Sabatini's financial leadership experience extends across multiple functional areas, including accounting, tax planning, and financial planning and analysis. These diverse responsibilities at Amgen and his more recent role at Capsida suggest that he possesses the breadth of knowledge necessary to oversee both the accounting operations and the broader financial management functions typically encompassed by a chief financial officer role, even on an interim basis.

Search for Permanent CFO Successor

Vir Biotechnology disclosed that it has initiated a search for a permanent successor to Jason O'Byrne in the Chief Financial Officer role. The filing does not provide details regarding the timeline, scope, or nature of the search process, such as whether the company is engaging an external search firm, considering internal candidates, or focusing on external recruitment. Investors may be watching for future announcements regarding the permanent CFO appointment and the conclusion of the interim period.

The interim appointment of Sabatini provides the company with experienced internal leadership during the search process while avoiding the immediate need for an external hire. The duration of the interim period and the company's ultimate CFO appointment decision may provide insight into the company's leadership priorities, succession planning maturity, and strategic direction.

Regulatory and Market Context

Vir Biotechnology is a Delaware corporation with its principal executive offices located in San Francisco, California. The company's common stock trades on the Nasdaq Global Select Market under the ticker symbol VIR. The company's Commission File Number is 001-39083, and its IRS Employer Identification Number is 81-2730369. As a publicly traded company on a major national securities exchange, Vir Biotechnology is subject to federal securities laws and regulations, including requirements for timely disclosure of material changes in executive leadership. The announcement of the CFO resignation and interim successor appointment was disclosed via a current report on Form 8-K, the standard disclosure vehicle for material events occurring outside the regular quarterly and annual reporting cycle.

Executive transitions in public biotechnology companies often attract investor attention given the importance of experienced financial leadership in managing capital allocation, regulatory compliance, and strategic financial planning within the sector. The immediate appointment of an internal interim successor, rather than a prolonged vacancy or external interim hire, may be interpreted by investors as a sign of preparedness and continuity planning.

Reporting and Certification Matters

The appointment of Sabatini as interim principal financial officer carries implications for the company's financial reporting responsibilities and certifications. Sabatini will assume responsibilities that may include or relate to the certification of financial statements and management's assessment of internal control over financial reporting under Sarbanes-Oxley Act Section 302 and 906. The transition of these responsibilities from O'Byrne to Sabatini effective August 3, 2026, represents a change in the executive officer responsible for these certification obligations. The company's disclosure does not specify the particular mechanics of how certification responsibilities will be allocated or transitioned during the interim period and any subsequent permanent CFO appointment.

Investors monitoring executive turnover in public companies often pay attention to changes in the certifying officer for financial statements, as such changes are required to be disclosed in periodic filings. The timing of Sabatini's interim appointment to coincide with O'Byrne's departure appears designed to ensure that a principal financial officer role remains continuously filled, avoiding any potential gaps in the financial reporting and certification function.